Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock

Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Todd Thomson sold 280,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $5.80, for a total value of $1,624,000.00. Following the sale, the director directly owned 904,795 shares in the company, valued at $5,247,811. This trade represents a 23.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Actuate Therapeutics Stock Performance

ACTU stock opened at $6.28 on Friday. The firm has a fifty day moving average price of $6.61 and a 200 day moving average price of $7.00. Actuate Therapeutics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $11.99. The firm has a market cap of $145.95 million, a PE ratio of -7.22 and a beta of -0.15.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02.

Institutional Trading of Actuate Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Sfmg LLC boosted its position in shares of Actuate Therapeutics by 32.3% during the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock valued at $89,000 after buying an additional 3,550 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Actuate Therapeutics by 98.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock worth $151,000 after acquiring an additional 11,105 shares during the last quarter. Bank of America Corp DE boosted its holdings in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after acquiring an additional 15,267 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Actuate Therapeutics by 492.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after acquiring an additional 15,393 shares during the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in Actuate Therapeutics in the second quarter worth $105,000.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Actuate Therapeutics in a research report on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Actuate Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.